| Assessment Status | Rapid review complete |
| HTA ID | 21033 |
| Drug | Durvalumab |
| Brand | Imfinzi® |
| Indication | In combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer. |
| Assessment Process | |
| Rapid review commissioned | 12/08/2021 |
| Rapid review completed | 09/09/2021 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that durvalumab not be considered for reimbursement at the submitted price* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
